The fund has secured over $100 million from the Business Development Bank of Canada, Fonds de solidarité FTQ, Teralys, Investissement Québec and the Caisse de dépôt et placement du Québec. (The Logic)

Talking point: With the backing of some of the country’s largest institutional investors, Amplitude is looking to capitalize on Canada’s booming biotech sector. It’s led by two former BDC fund managers—Jean-François Pariseau and Dion Madsen—and will manage BDC’s current biotech venture portfolio, as well. If Amplitude succeeds, more of the economic benefit will stay in Canada. It isn’t the only institution working on this: in February, The Logic reported that MaRS Innovation had hired three lobbyists to ask for “tens of millions” to help Canadian biotech startups stay in the country. International investors are increasingly interested in Canadian biotech startups, too. In April, Waltham, Mass.-based healthtech firm PerkinElmer gave up to $2 million for a lab in Waterloo.